<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">sechenov</journal-id><journal-title-group><journal-title xml:lang="en">Sechenov Medical Journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Сеченовский вестник</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2218-7332</issn><issn pub-type="epub">2658-3348</issn><publisher><publisher-name>Сеченовский Университет</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47093/2218-7332.2021.12.1.74-82</article-id><article-id custom-type="elpub" pub-id-type="custom">sechenov-217</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ONCOLOGY</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОНКОЛОГИЯ</subject></subj-group></article-categories><title-group><article-title>Approaches for the prevention and treatment of venous thromboembolism in a patient with anaplastic astrocytoma: a case report</article-title><trans-title-group xml:lang="ru"><trans-title>Проблемы профилактики и лечения тромбоэмболических осложнений у пациента с анапластической астроцитомой:  описание клинического случая</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6073-328X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Павлова</surname><given-names>М. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Pavlova</surname><given-names>M. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Павлова Мария Геннадиевна, канд. мед. наук, доцент кафедры эндокринологии № 1</p><p>ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991</p></bio><bio xml:lang="en"><p>Maria G. Pavlova, Cand. of Sci. (Medicine), Associate Professor, Department of Endocrinology № 1</p><p>8/2, Trubetskaya str., Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8637-1483</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Амергулов</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Amergulov</surname><given-names>I. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Амергулов Илья Ильич, клинический ординатор кафедры эндокринологии № 1</p><p>ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991</p><p>+7 (916) 518-20-51</p></bio><bio xml:lang="en"><p>Ilya I. Amergulov, resident at the Department of Endocrinology № 1</p><p>8/2, Trubetskaya str., Moscow, 119991</p><p>+7 (916) 518-20-51</p></bio><email xlink:type="simple">ilya_a94@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4680-0746</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лиходей</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Likhodey</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лиходей Наталья Вячеславовна, врач-эндокринолог УКБ № 2</p><p>ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991</p></bio><bio xml:lang="en"><p>Natalia V. Likhodey, endocrinologist, University clinic № 2</p><p>8/2, Trubetskaya str., Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1762-4760</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Куркина</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kurkina</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Куркина Ирина Александровна, врач-трансфузиолог, заведующая отделением клинической трансфузиологии Лабораторно-гемотрансфузиологического комплекса</p><p>ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991</p></bio><bio xml:lang="en"><p>Irina A. Kurkina, Transfusiologist, Head of Clinical Transfusiology Department, Laboratory Hematological and Transfusiological Complex of Clinical Center</p><p>8/2, Trubetskaya str., Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8505-5526</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Глинкина</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Glinkina</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Глинкина Ирина Владимировна, канд. мед. наук, доцент кафедры эндокринологии № 1</p><p>ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991</p></bio><bio xml:lang="en"><p>Irina V. Glinkina, Cand. of Sci. (Medicine), Associate Professor, Department of Endocrinology № 1</p><p>8/2, Trubetskaya str., Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8607-3635</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Желудкова</surname><given-names>О. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Zheludkova</surname><given-names>O. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Желудкова Ольга Григорьевна, д-р мед. наук, профессор, врач-онколог онкологического отделения № 2 (с нейрохирургией)</p><p>ул. Авиаторов, д. 38, г. Москва, 119620</p></bio><bio xml:lang="en"><p>Olga G. Zheludkova, Dr. of Sci. (Medicine), Professor, Oncologist, Oncology Department № 2</p><p>38, Aviatorov str., Moscow, 119620</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2870-3301</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гиляров</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Gilyarov</surname><given-names>M. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гиляров Михаил Юрьевич, д-р мед. наук, профессор кафедры кардиологии, функциональной и ультразвуковой диагностики; заместитель главного врача по терапевтической помощи</p><p>ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991; Ленинский проспект, д. 8, г. Москва, 119049</p></bio><bio xml:lang="en"><p>Mihail Yu. Gilyarov, Dr. of Sci. (Medicine), Professor, Department of Cardiology, Functional and Ultrasound Diagnostics; Deputy Hospital Chief Physician (Therapy)</p><p>8/2, Trubetskaya str., Moscow, 119991; 8, Leninskiy ave., Moscow, 119049</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУЗ «Научно-практический центр специализированной медицинской помощи детям им. В.Ф. Войно-Ясенецкого» Департамента здравоохранения города Москвы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Scientific and Practical Center for Specialized Medical Care for Children named after V.F. Voino-Yasenetsky</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет); ГБУЗ «Городская клиническая больница № 1 им. Н.И. Пирогова» Департамента здравоохранения города Москвы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov First Moscow State Medical University (Sechenov University); City Clinical Hospital № 1 named after N.I. Pirogov</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>29</day><month>04</month><year>2021</year></pub-date><volume>12</volume><issue>1</issue><fpage>74</fpage><lpage>82</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Pavlova M.G., Amergulov I.I., Likhodey N.V., Kurkina I.A., Glinkina I.V., Zheludkova O.G., Gilyarov M.Y., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Павлова М.Г., Амергулов И.И., Лиходей Н.В., Куркина И.А., Глинкина И.В., Желудкова О.Г., Гиляров М.Ю.</copyright-holder><copyright-holder xml:lang="en">Pavlova M.G., Amergulov I.I., Likhodey N.V., Kurkina I.A., Glinkina I.V., Zheludkova O.G., Gilyarov M.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.sechenovmedj.com/jour/article/view/217">https://www.sechenovmedj.com/jour/article/view/217</self-uri><abstract><p>Venous thromboembolism occurs in 48–200 out of 1,000 patients with brain cancer per year, which is significantly more frequent than in general population.</p><sec><title>Case report</title><p>Case report. A female patient had surgical treatment of anaplastic astrocytoma following radiotherapy and chemotherapy (temozolomide, irinotecan, bevacizumab) at the age of 17 years old. She also received dexamethasone. At the age of 20 years, she developed cancer recurrence, that required chemotherapy. After chemotherapy had been initiated, the patient developed deep vein thrombosis of the legs. Rivaroxaban 20 mg/d for 2.5 months with the subsequent switch to enoxaparin 60 mg/d showed no recanalization. Enoxaparin dose increasing up to 160 mg/d demonstrated incomplete recanalization, however, superficial venous thrombosis of the legs developed. Combination therapy with enoxaparin plus warfarin resulted in further deep and superficial veins recanalization.</p></sec><sec><title>Discussion</title><p>Discussion. In cancer-associated venous thromboembolism that is resistant to low molecular weight heparin monotherapy, short-term combination therapy with low molecular weight heparin and vitamin K antagonists can be considered. However, in recurrent cancer standard treatment protocols can be ineffective.</p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Ведение</title><p>Ведение. Анапластическая астроцитома (АА) относится к глиомам высокой степени злокачественности. У пациентов с АА ВТЭ (венозные тромбоэмболии) развиваются значительно чаще, чем в общей популяции, что связано не только с прогрессирования основного онкологического заболевания, но и с развитием осложнений химио-лучевой терапии.</p></sec><sec><title>Описание случая</title><p>Описание случая. После проведённой в возрасте 17 лет хирургической резекции АА, последующей лучевой терапии (с назначением дексаметазона 8 мг/сутки) и таргетной терапии бевацизумабом у пациентки в 20 лет развился тромбоз глубоких вен (ГВ) нижних конечностей. На фоне ривароксабана в дозе 20 мг/сутки в течение 2-х месяцев с последующим переводом на эноксапарин в дозе 60 мг/сутки реканализация отсутствовала. Под контролем показателей коагулограммы доза эноксапарина увеличена до 160 мг/сутки – также без эффекта. Далее 7 дней проводилась комбинированная терапия НМГ (низкомолекулярным гепарином) и варфарином до достижения и сохранения в течение 2-х дней целевого уровня международного нормализованного отношения (МНО), что в дальнейшем привело к пристеночной реканализации на всех уровнях от 20 до 60%.</p></sec><sec><title>Заключение</title><p>Заключение. Лечение ВТЭ, ассоциированного с злокачественным образованием, предполагает назначение НМГ или ривароксабана. Однако следует проявлять осторожность при совместном назначении пероральных антикоагулянтов и индукторов CYP3A4 и P-гликопротеина, которые могут снижать эффект первых. В отдельных случаях, резистентных к монотерапии НМГ, возможно проведение курсовой комбинированной терапии НМГ и антагонистов витамина К.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>анапластическая астроцитома</kwd><kwd>ривароксабан</kwd><kwd>эноксапарин</kwd><kwd>антикоагулянты</kwd><kwd>низкомолекулярный гепарин</kwd><kwd>варфарин</kwd><kwd>химиолучевая терапия</kwd><kwd>тромбоз глубоких вен нижних конечностей</kwd></kwd-group><kwd-group xml:lang="en"><kwd>anaplastic astrocytoma</kwd><kwd>rivaroxaban</kwd><kwd>enoxaparin</kwd><kwd>anticoagulants</kwd><kwd>low molecular weight heparin</kwd><kwd>warfarin</kwd><kwd>chemoradiation therapy</kwd><kwd>deep vein thrombosis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Louis D.N., Perry A., Reifenberger G., et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016; 131(6): 803–820. https://doi.org/10.1007/s00401-016-1545-1 PMID: 27157931</mixed-citation><mixed-citation xml:lang="en">Louis D.N., Perry A., Reifenberger G., et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016; 131(6): 803–820. https://doi.org/10.1007/s00401-016-1545-1 PMID: 27157931</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ostrom Q.T., Gittleman H., Liao P., et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 2014;16(4): iv1–63. https://doi.org/10.1093/neuonc/nou223 PMID: 25304271</mixed-citation><mixed-citation xml:lang="en">Ostrom Q.T., Gittleman H., Liao P., et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 2014;16(4): iv1–63. https://doi.org/10.1093/neuonc/nou223 PMID: 25304271</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Юдина А.Е., Павлова М.Г., Сотников В.М. и др. Тест с глюкагоном в диагностике вторичной надпочечниковой недостаточности после краниоспинального облучения: возможность применения, особенности проведения, диагностическая информативность. Проблемы Эндокринологии. 2019; 65(4): 227–235. https://doi.org/10.14341/probl10219 PMID: 32202724</mixed-citation><mixed-citation xml:lang="en">Yudina A.E., Pavlova M.G., Sotnikov V.M., et al. Test s glyukagonom v diagnostike vtorichnoi nadpochechnikovoi nedostatochnosti posle kraniospinal’nogo oblucheniya: vozmozhnost’ primeneniya, osobennosti provedeniya, diagnosticheskaya informativnost’. [The glucagon test in diagnosis of secondary adrenal insufficiency after craniospinal irradiation: the feasibility of application, the features of performing the test, and its diagnostic informativity]. Problems of Endocrinology. 2019; 65(4): 227–235 (In Russian). https://doi.org/10.14341/probl10219 PMID: 32202724</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Боброва Е.И., Павлова М.Г., Сотников В.М. и др. Гипопитуитаризм после облучения гипоталамогипофизарной системы. Клиническая и экспериментальная тиреоидология. 2013; 9(3): 15–20.</mixed-citation><mixed-citation xml:lang="en">Bobrova E.I., Pavlova M.G., Sotnikov V.M., et al. Gipopituitarizm posle oblucheniya gipotalamogipofizarnoi sistemy. [Hypopituitarism after radiotherapy on pituitary-hypothalamus area]. Clinical and experimental thyroidology, 2013; 9(3): 15–20 (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Perry J.R. Thromboembolic disease in patients with high-grade glioma. Neuro Oncol. 2012; 14(4): iv73–80. https://doi.org/10.1093/neuonc/nos197 PMID: 23095833</mixed-citation><mixed-citation xml:lang="en">Perry J.R. Thromboembolic disease in patients with high-grade glioma. Neuro Oncol. 2012; 14(4): iv73–80. https://doi.org/10.1093/neuonc/nos197 PMID: 23095833</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Сомонова О.В., Антух Э.А., Долгушин Б.И. и др. Практические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных. Злокачественные опухоли. 2020; 10(3s2-2): 131–140. https://doi.org/10.18027/2224-5057-2020-10-3s2-47</mixed-citation><mixed-citation xml:lang="en">Somonova O.V., Antukh EH.A., Dolgushin B.I., et al. Prakticheskie rekomendatsii po profilaktike i lecheniyu tromboehmbolicheskikh oslozhnenii u onkologicheskikh bol’nykh. [Clinical Guidelines for the Prevention and Management of Thromboembolic complications in Oncological Patients]. Malignant tumors. 2020; 10(3s2-2): 131–140 (In Russian). https://doi.org/10.18027/2224-5057-2020-10-3s2-47</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Farge D., Frere C., Connors J.M., et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019; 20(10): e566–581. https://doi.org/10.1016/S1470-2045(19)30336-5 PMID: 31492632</mixed-citation><mixed-citation xml:lang="en">Farge D., Frere C., Connors J.M., et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019; 20(10): e566–581. https://doi.org/10.1016/S1470-2045(19)30336-5 PMID: 31492632</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Weller M., van den Bent M., Hopkins K., et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014; 15(9): e395–403. https://doi.org/10.1016/S1470-2045(14)70011-7 PMID: 25079102</mixed-citation><mixed-citation xml:lang="en">Weller M., van den Bent M., Hopkins K., et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014; 15(9): e395–403. https://doi.org/10.1016/S1470-2045(14)70011-7 PMID: 25079102</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Key N.S., Khorana A.A., Kuderer N.M., et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020; 38(5): 496–520. https://doi.org/10.1200/JCO.19.01461 PMID: 31381464</mixed-citation><mixed-citation xml:lang="en">Key N.S., Khorana A.A., Kuderer N.M., et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020; 38(5): 496–520. https://doi.org/10.1200/JCO.19.01461 PMID: 31381464</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Weintraub N.L., Jones W.K., Manka D. Understanding radiationinduced vascular disease. J Am Coll Cardiol. 2010; 55(12): 1237–1239. https://doi.org/10.1016/j.jacc.2009.11.053 PMID: 20298931</mixed-citation><mixed-citation xml:lang="en">Weintraub N.L., Jones W.K., Manka D. Understanding radiationinduced vascular disease. J Am Coll Cardiol. 2010; 55(12): 1237–1239. https://doi.org/10.1016/j.jacc.2009.11.053 PMID: 20298931</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Koo C.M., Vissapragada R., Sharp R., et al. ABO blood group related venous thrombosis risk in patients with peripherally inserted central catheters. Br J Radiol. 2018; 91(1082): 20170560. https://doi.org/10.1259/bjr.20170560 PMID: 29125332</mixed-citation><mixed-citation xml:lang="en">Koo C.M., Vissapragada R., Sharp R., et al. ABO blood group related venous thrombosis risk in patients with peripherally inserted central catheters. Br J Radiol. 2018; 91(1082): 20170560. https://doi.org/10.1259/bjr.20170560 PMID: 29125332</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Oppelt P., Betbadal A., Nayak L. Approach to chemotherapy-associated thrombosis. Vasc Med. 2015; 20(2): 153–161. https://doi.org/10.1177/1358863X14568705 PMID: 25832603</mixed-citation><mixed-citation xml:lang="en">Oppelt P., Betbadal A., Nayak L. Approach to chemotherapy-associated thrombosis. Vasc Med. 2015; 20(2): 153–161. https://doi.org/10.1177/1358863X14568705 PMID: 25832603</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Steffel J., Verhamme P., Potpara T.S., et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39(16): 1330–1393. https://doi.org/10.1093/eurheartj/ehy136 PMID: 29562325</mixed-citation><mixed-citation xml:lang="en">Steffel J., Verhamme P., Potpara T.S., et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39(16): 1330–1393. https://doi.org/10.1093/eurheartj/ehy136 PMID: 29562325</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Agnelli G., Buller H.R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369(9): 799–808. https://doi.org/10.1056/NEJMoa1302507 PMID: 23808982</mixed-citation><mixed-citation xml:lang="en">Agnelli G., Buller H.R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369(9): 799–808. https://doi.org/10.1056/NEJMoa1302507 PMID: 23808982</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Borges C., Simões J., Reis J., et al. Venous thromboembolism and intracranial hemorrhage in patients with high-grade glioma. Annals of Oncology. 2019; 30 (Supplement 5): v152–153, https://doi.org/10.1093/annonc/mdz243.029</mixed-citation><mixed-citation xml:lang="en">Borges C., Simões J., Reis J., et al. Venous thromboembolism and intracranial hemorrhage in patients with high-grade glioma. Annals of Oncology. 2019; 30 (Supplement 5): v152–153, https://doi.org/10.1093/annonc/mdz243.029</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ohashi Y., Ikeda M., Kunitoh H., et al. Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry. Jpn J Clin Oncol. 2020 Oct 22; 50(11): 1246–1253. Erratum in: Jpn J Clin Oncol. 2020 Oct 22; 50(11): 1346. https://doi.org/:10.1093/jjco/hyaa112 PMID: 32715307</mixed-citation><mixed-citation xml:lang="en">Ohashi Y., Ikeda M., Kunitoh H., et al. Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry. Jpn J Clin Oncol. 2020 Oct 22; 50(11): 1246–1253. Erratum in: Jpn J Clin Oncol. 2020 Oct 22; 50(11): 1346. https://doi.org/:10.1093/jjco/hyaa112 PMID: 32715307</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
